Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, Topics May 09 | 2025Insulet, Senseonics, Skye, and Biocon Q1 ‘25 Earnings; Zealand and Roche Make it Official; Akero Presents MASH Data at EASL 2025; Lilly Initiates New Ph3 Tirzepatide Study in T1DM Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics May 08 | 2025Novo London, Zealand, MannKind, Xeris, and Viatris Q1 ‘25 Earnings; US Judge Supports FDA’s Removal of Lilly’s GLP-1RA From Shortage List; Lilly Makes Changes to Executive LeadershipPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics May 07 | 2025Beta Bionics Q1 ‘25 Earnings; MetaVia Presents MASH data at EASL 2025Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other, Topics May 07 | 2025Novo Q1 ‘25 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 06 | 2025Vertex, Biomea, and Esperion Q1 ‘25 Earnings; Oura Launches Glucose Feature Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 02 | 2025FDA accepts Oral Sema NDA; Dexcom and Amgen Q1 ‘25 Earnings; Lilly Launches New Mounjaro Campaign Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics May 01 | 2025Lilly and Madrigal Q1 ’25 Earnings; Wegovy Receives Preferred Status from CVSPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 30 | 2025Lilly Integrates with WeightWatchers, Partners with Creyon, and Initiates New Ph3 Orfo Trials; Tandem Q1 ’25 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 29 | 2025Novo Partners with Telehealth Providers; AstraZeneca, Pfizer, Novartis, and Regeneron Q1 ’25 Earnings; Abbott and Epic CGM Integration; Eversense 365 to Integrate with twiist AID SystemPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 28 | 2025Insulet Hires New CEO; Galmed Sublingual Semaglutide; Vutrisiran ATTR-CM CHMP Opinion Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 25 | 2025AbbVie Q1 ‘25 Earnings; Madrigal Hires Ex-Novartis CVRM Development LeadPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 25 | 2025Medtronic Seeks Interoperability; Roche, Viking, Sanofi, and Merck Q1 ‘25 Earnings; Zealand Enrolls First Patient in Ph2 T2DM Study; Esperion R&D Day 2025Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 23 | 2025Lilly’s Two New Ph3 Studies in Obesity; Ascletis Ph1 Obesity Study Topline Results; Zealand Hires Ex-Lilly Exec; Lilly Sues Compounders...Again Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 23 | 2025Novo Files HD Oral Sema; Roche Expands US Manufacturing; MetaVia Additional Ph1 Obesity Results; Ypsomed Sells Diabetes Care Business; Biolinq $100M Series C; April CHMP Agenda Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Apr 21 | 2025Medtronic Receives FDA Approval for Simplera + MiniMed 780GPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Apr 17 | 2025Lilly Ph3 Orforglipron T2DM Topline ResultsPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Apr 16 | 2025Abbott Q1 ’25 Earnings Update Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 15 | 2025Zealand Accelerates Hiring & Initiates New Ph2 Petrelintide Study; Merck Licenses Oral Drug Delivery Platform; MetaVia Ph1 Obesity Results; Skye Preclinical Obesity Results Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 14 | 2025Pfizer Discontinues Danuglipron in Obesity; Verve Shares Initial Ph1b HeFH/CAD Data; Novo Warns Against Counterfeit Ozempic; Syntis Announces Preliminary Data in Obesity Purchase Blast
$599
Posted in: Glucose Monitoring, Topics Apr 10 | 2025Dexcom Receives FDA Clearance for G7 15 Day CGMPurchase Blast